Active substances

Rosuvastatin + amlodipine + perindopril›

C10BX14 Cardiovascular system | Lipid modifying agents | Lipid modifying agents, combinations | Lipid modifying agents in combination with other drugs

Indicated for: dyslipidemia

Rosuvastatin + ezetimibe›

C10BA06 Cardiovascular system | Lipid modifying agents | Lipid modifying agents, combinations | Combinations of various lipid modifying agents

Indicated for: dyslipidemia

Rosuvastatin + fenofibrate›

C10BA09 Cardiovascular system | Lipid modifying agents | Lipid modifying agents, combinations | Combinations of various lipid modifying agents

Indicated for: mixed dyslipidemia; hypercholesterolemia and hypertriglyceridemia

Rosuvastatin + perindopril›

C10BX21 Cardiovascular system | Lipid modifying agents | Lipid modifying agents, combinations | Lipid modifying agents in combination with other drugs

Indicated for: dyslipidemia

Rosuvastatin + perindopril + indapamide›

C10BX13 Cardiovascular system | Lipid modifying agents | Lipid modifying agents, combinations | Lipid modifying agents in combination with other drugs

Indicated for: dyslipidemia

Rosuvastatin + valsartan›

C10BX10 Cardiovascular system | Lipid modifying agents | Lipid modifying agents, combinations | Lipid modifying agents in combination with other drugs

Indicated for: dyslipidemia

Rotavirus vaccine›

J07BH01 Antiinfectives for systemic use | Viral vaccines | Rotavirus diarrhea vaccines

Indicated for: prevention of rotavirus gastroenteritis

Rotigotine›

N04BC09 Nervous system | Dopaminergic agents | Dopamine agonists

Indicated for: Parkinson's disease

Roxadustat›

B03XA05 Blood and blood forming organs | Other antianemic preparations

Indicated for: anemia

Roxithromycin›

J01FA06 Antiinfectives for systemic use | Macrolides, lincosamides and streptogramins

Indicated for: bacterial infections

Rozanolixizumab›

L04AL02 Antineoplastic and immunomodulating agents | Immunosuppressants | Immunosuppressants | Neonatal fragment crystallizable receptor (fcrn) inhibitors

Indicated for: myasthenia gravis

Rufinamide›

N03AF03 Nervous system | Antiepileptics | Antiepileptics | Carboxamide derivatives

Indicated for: epilepsy

Rupatadine›

R06AX28 Respiratory system | Antihistamines for systemic use | Antihistamines for systemic use | Other antihistamines for systemic use

Indicated for: allergic rhinitis; urticaria

Rurioctocog alfa pegol›

B02BD02 Blood and blood forming organs | Vitamin k and other hemostatics | Blood coagulation factors

Indicated for: bleeding; coagulation disorders

Ruscus extract + hesperidin methyl chalcone + ascorbic acid›

C05CXN1 Cardiovascular system | Capillary stabilizing agents | Other capillary stabilizing agents

Indicated for: venous insufficiency; hemorrhoids

Rutoside›

C05CA51 Cardiovascular system | Capillary stabilizing agents | Bioflavonoids

Indicated for: chronic venous insufficiency; capillary fragility

Rutoside + ascorbic acid›

C05CA51 Cardiovascular system | Capillary stabilizing agents | Bioflavonoids

Indicated for: vitamin deficiency

Rutoside + bromelain + trypsin›

M09AB52 Musculo-skeletal system | Other drugs for disorders of the musculo-skeletal system | Other drugs for disorders of the musculo-skeletal system | Enzymes

Indicated for: inflammation; post-traumatic edema

Ruxolitinib›

L01EJ01 Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Janus-associated kinase (JAK) inhibitors

Indicated for: cancer